Evidence map›Paper›PMID 30597867›Full record

ArticleInternational journal of molecular sciences2018

Peptidylarginine Deiminases Post-Translationally Deiminate Prohibitin and Modulate Extracellular Vesicle Release and MicroRNAs in Glioblastoma Multiforme.

Uchini S Kosgodage, Pinar Uysal-Onganer, Amy MacLatchy, Igor Kraev, Nicholas P Chatterton, Anthony P Nicholas, Jameel M Inal, Sigrun Lange

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Citrullination and the protein code: crosstalk between post-translational modifications in cancer.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Uchini S KosgodageCellular and Molecular Immunology Research Centre, School of Human Sciences, London Metropolitan University, London N7 8DB, UK. uchini22@hotmail.co.uk.
Pinar Uysal-OnganerCancer Research Group, School of Life Sciences, University of Westminster, London W1W 6UW, UK. P.onganer@westminster.ac.uk.
Amy MacLatchyResearch Centre for Optimal Health, School of Life Sciences, University of Westminster, London W1W 6UW, UK. amy.maclatchy@my.westminster.ac.uk.
Igor KraevSchool of Life, Health and Chemical Sciences, The Open University, Walton Hall, Milton Keynes MK7 6AA, UK. igor.kraev@open.ac.uk.
Nicholas P ChattertonSchool of Life, Health and Chemical Sciences, The Open University, Walton Hall, Milton Keynes MK7 6AA, UK. nicholas.chatterton@open.ac.uk.
Anthony P NicholasDepartment of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. anicholas@uabmc.edu.
Jameel M InalExtracellular Vesicle Research Unit and Bioscience Research Group, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK. j.inal@herts.ac.uk.
Sigrun LangeTissue Architecture and Regeneration Research Group, School of Life Sciences, University of Westminster, London W1W 6UW, UK. S.lange@westminster.ac.uk.
University of Westminster · GBThe Open University · GBLondon Metropolitan University · GBUniversity of Alabama at Birmingham · USUniversity of Hertfordshire · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most aggressive form of adult primary malignant brain tumour with poor prognosis. Extracellular vesicles (EVs) are a key-mediator through which GBM cells promote a pro-oncogenic microenvironment. Peptidylarginine deiminases (PADs), which catalyze the post-translational protein deimination of target proteins, are implicated in cancer, including via EV modulation. Pan-PAD inhibitor Cl-amidine affected EV release from GBM cells, and EV related microRNA cargo, with reduced pro-oncogenic microRNA21 and increased anti-oncogenic microRNA126, also in combinatory treatment with the chemotherapeutic agent temozolomide (TMZ). The GBM cell lines under study, LN18 and LN229, differed in PAD2, PAD3 and PAD4 isozyme expression. Various cytoskeletal, nuclear and mitochondrial proteins were identified to be deiminated in GBM, including prohibitin (PHB), a key protein in mitochondrial integrity and also involved in chemo-resistance. Post-translational deimination of PHB, and PHB protein levels, were reduced after 1 h treatment with pan-PAD inhibitor Cl-amidine in GBM cells. Histone H3 deimination was also reduced following Cl-amidine treatment. Multifaceted roles for PADs on EV-mediated pathways, as well as deimination of mitochondrial, nuclear and invadopodia related proteins, highlight PADs as novel targets for modulating GBM tumour communication.

Indexed as

Antineoplastic AgentsBiological TransportCell Line, TumorCell SurvivalChromatography, LiquidExtracellular VesiclesGlioblastomaHistonesHumansMicroRNAsOrnithineProhibitinsProtein-Arginine DeiminasesProtein Processing, Post-TranslationalProteomeProteomicsAntineoplastic AgentsHistonesMicroRNAsN-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amideOrnithinePHB protein, humanProhibitinsProtein-Arginine DeiminasesProteomedeiminated histone H3extracellular vesicles (EVs)glioblastoma multiforme (GBM)peptidylarginine deiminase (PAD)prohibitin (PHB)

Identifiers

PMID30597867
PMCPMC6337164
OpenAlexW2908356928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.